Related Experiment Video
Updated: Jul 17, 2026
09:33
Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling
Published on: March 20, 2018
Cytochromes P450: decision-making tools for personalized therapeutics
Michael Murray1, Nenad Petrovic
1Pharmacogenomics and Drug Development Group, Faculty of Pharmacy, University of Sydney, NSW2006, Australia. michaelm@pharm.usyd.edu.au
Current Opinion in Molecular Therapeutics
|January 25, 2007
Summary
Individualized medicine optimizes drug therapy by considering patient variations in cytochrome P450 (CYP) enzymes. Understanding CYP pharmacogenetics ensures effective drug dosages and minimizes adverse effects for personalized treatment.
Area of Science:
- Pharmacogenetics
- Drug Metabolism
- Personalized Medicine
Background:
- Patient responses to standard drug regimens vary significantly, ranging from subtherapeutic to toxic levels.
- Cytochrome P450 (CYP) enzymes are crucial for drug metabolism, influencing drug action duration.
- Genetic variations (allelic variants) and environmental factors affect CYP enzyme function and expression.
Purpose of the Study:
- To review recent advancements in CYP pharmacogenetics.
- To highlight the role of CYP enzymes in individualized drug therapy.
- To discuss the impact of genetic and polygenic factors on personalized drug regimens.
Main Methods:
- Review of recent literature on CYP pharmacogenetics.
- Characterization of substrate- and inhibitor-specificity of CYP variant enzymes.
- Analysis of evidence for polygenic factors in drug regimen design.
Main Results:
- CYP allelic variants can lead to defective or absent enzymes, impacting drug metabolism.
- Non-genetic factors can induce or inhibit CYP enzyme activity.
- Patients may require adjusted drug doses based on their CYP metabolic capacity.
Conclusions:
- CYP pharmacogenetics is essential for optimizing drug therapy and minimizing toxicity.
- Personalized drug regimens must account for individual CYP enzyme profiles.
- Polygenic factors increasingly influence the development of tailored drug treatments.
Related Concept Videos
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...